HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Attal, M. Articles by Harousseau, J.-L. Search for Related Content PubMed PubMed Citation Articles by Attal, M. Articles by Harousseau, J.-L. Social Bookmarking                   What's this?

Stem Cell Transplantation in Multiple Myeloma

Correspondence: Michel Attal, MD, Hopital Purpan, Place du Dr. Baylac, 31059 Toulouse, France; Phone +33 (5) 61777784; Fax +33 (5) 61777541; attal.m{at}chu-toulouse.fr

Abstract

Multiple myeloma (MM) is one of the key hematologic malignancies in which the impact of dose intensity has been demonstrated. Consequently, in 2005, MM was the most common disease for which autologous stem cell transplantation (ASCT) was indicated both in Europe and in the U.S. However, ASCT is not curative, and most patients relapse within a median of 3 years. Novel agents such as thalidomide (Thalidomid), bortezomib (Velcade), or lenalidomide (Revlimid) have been introduced to improve high-dose therapy, and promising results have been reported. Conversely, results from myeloablative allogeneic stem cell transplantation remain disappointing due to high transplantation-related mortality, justifying the exploration of strategies such as reduced-intensity conditioning, which have been shown to be feasible but for which proof of efficacy requires continued study.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?